PCYC-1111-CA: Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

      To access the most up-to-date information on this study,
      please refer to this page at ClinicalTrials.gov.

Official Title

A Multicenter Phase II Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765, in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)

Purpose

This study will evaluate the safety and preliminary efficacy of PCI-32765 in relapsed or relapsed and refractory multiple myeloma (MM)